Heron (HRTX) Appoints Kimberly J. Manhard As Executive Vice President Of Drug Development

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of Kimberly J. Manhard as Executive Vice President of Drug Development. Ms. Manhard joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.

Read more on